T CELL RECOGNITION OF LUNG CANCERS IN MAN

Information

  • Research Project
  • 3491510
  • ApplicationId
    3491510
  • Core Project Number
    R43CA042699
  • Full Project Number
    1R43CA042699-01
  • Serial Number
    42699
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/5/1986 - 38 years ago
  • Project End Date
    2/28/1987 - 37 years ago
  • Program Officer Name
  • Budget Start Date
    9/5/1986 - 38 years ago
  • Budget End Date
    2/28/1987 - 37 years ago
  • Fiscal Year
    1986
  • Support Year
    1
  • Suffix
  • Award Notice Date
    -

T CELL RECOGNITION OF LUNG CANCERS IN MAN

The long term objective of this project is to understand the molecular basis of T cell recognition of tumor antigens of lung carcinoma. The specific aims of the proposed study are 1). to characterize the genes encoding T cell antigen receptors (TCAR) from the tumor infiltrating lymphocytes; 2). to investigate whether there is a limited expression of T cell clonotypes directed against tumor cells at the site of lung tumors. A T cell clonotype is defined by TCAR, which is composed of an alpha and a beta polypeptide chain. Each alpha and beta chain consist of Variable (V) and Diversity (D), Joining (J) and Constant (C) domains. Estimated total numbers of V beta genes of the TCAR in the murine system are around twenty. Phase I efforts will include A). an analysis of the total V beta gene repertoire available in humans and B). an analysis of those V beta genes expressed in the tumor derived T cells. For these studies a CDNA library will be prepared from tumor derived T cells using a 5' beta constant region sequence as a primer and appropriate phages as vector. Comparative analysis of these tumor derived V beta DNA sequences with the complete repertoire of V beta sequences obtained from a large peripheral T cell library will be done. These DNA sequence analyses may be extended to the V alpha genes as well as D and J regions of alpha and beta genes. The molecular analysis of the tumor derived T cells may provide a rational basis for developing the T cell receptor oriented DNA probes and monoclonal antibodies for diagnosing and monitoring lung cancer patients.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    396
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    SSS
  • Study Section Name
  • Organization Name
    AVANT IMMUNOTHERAPEUTICS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    NEEDHAM
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    024942725
  • Organization District
    UNITED STATES